Jeffrey Cooper
Direttore/Membro del Consiglio presso Nexcella, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Randy Meier | M | 65 | 18 anni | |
| George Davis | M | 53 | 20 anni | |
| Stuart Bunting | M | - | 16 anni | |
| Philip Lo Scalzo | M | - | 17 anni | |
| Ed Borkowski | M | 64 |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 anni |
| Henry McKinnell | M | 81 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 anni |
| Mary Coleman | M | 80 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 anni |
| Henry Fuchs | M | 66 | 15 anni | |
| Eduardo Von Pervieux | M | - | 16 anni | |
| Brad Glasscock | M | - | 12 anni | |
| Ilya Rachman | M | 52 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | - |
| Gabriel Morris | M | 38 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jean-Jacques Bienaimé | M | 70 | 19 anni | |
| Jeff Ajer | M | 61 | 19 anni | |
| Dennis Brown | M | 74 |
Matrix Pharmaceutical, Inc.
 Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 14 anni |
| Pierre LaPalme | M | 83 | 12 anni | |
| Stephen Dilly | M | 64 | 2 anni | |
| Justin T. Huang | M | - | - | |
| Nick Glover | M | 55 | 6 anni | |
| V. Lawlis | M | 72 | 17 anni | |
| Paul Freiman | M | 89 |
Syntex Corp.
| 6 anni |
| Michael Metzger | M | 53 | - | |
| Robert E. Pelzer | M | 70 | 7 anni | |
| Mary Christina Thomson | F | 53 | 2 anni | |
| Herbert Cross | M | 52 | 2 anni | |
| Ambrose Bailey | M | 60 | - | |
| Albert Cha | M | 51 | 2 anni | |
| Patrick Heron | M | 53 | 1 anni | |
| Donald Parfet | M | 71 | 4 anni | |
| James Topper | M | 62 | 3 anni | |
| Dennis Podlesak | M | 66 | 1 anni | |
| Laurent Fischer | M | 60 | 1 anni | |
| Michael Grey | M | 71 | 16 anni | |
| Kevin Thomas Ryan | M | - | - | |
| Mark Wood | M | 57 | 9 anni | |
| James Smith | M | 54 | 8 anni | |
| Gaurav Aggarwal | M | 51 | 3 anni | |
| Mona Ashiya | M | 55 | 3 anni | |
| James Wilson | M | 80 |
Syntex Corp.
| 3 anni |
| Georgia Erbez | F | 57 | 1 anni | |
| Ian Clements | M | 55 | 1 anni | |
| Tran Nguyen | M | 50 | 3 anni | |
| Christy Oliger | F | 54 | 1 anni | |
| Barbara Klencke | M | 66 | 7 anni | |
| Andrew Sinclair | M | 52 | 3 anni | |
| Daniel J. Estes | M | 43 | 2 anni | |
| Brigitte Smith | F | 56 | 9 anni | |
| Fredric D. Price | M | 78 | 4 anni | |
| Diane Gardiner | F | - | - | |
| Eckard Weber | M | 73 | 1 anni | |
| Ken Bate | M | 73 | 7 anni | |
| Louis C. Drapeau | M | 79 | 3 anni | |
| Donald Joseph | M | 70 | 2 anni | |
| Kim Tsuchimoto | F | 61 | 8 anni | |
| Andrew Fromkin | M | 58 | 1 anni | |
| Craig Collard | M | 58 | 2 anni | |
| Andrew Allen | M | 57 | 5 anni | |
| James R. Glynn | M | 77 |
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 2 anni |
| William Young | M | 79 | 5 anni | |
| Dennis J. Henner | M | 72 | 8 anni | |
| Stephen M. Kaufhold | M | - | - | |
| Gwen Melincoff | M | 72 | 2 anni | |
| Emma McCann | F | - | 8 anni | |
| Alan J. Lewis | M | 78 | 15 anni | |
| Alvin Vitangcol | M | 49 | 3 anni | |
| Sandra Shpilberg | F | 48 | 9 anni | |
| Nicole Onetto | M | 71 | 4 anni | |
| David Ludvigson | M | 74 |
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | 2 anni |
| Laurie Alsup | M | 70 | 2 anni | |
| Christopher Starr | M | 71 | 9 anni | |
| James Brown | M | 67 |
Syntex Corp.
| 10 anni |
| Scott Bizily | M | 52 | 9 anni | |
| Wolfgang Dummer | M | 58 | 4 anni | |
| Elizabeth Ng | F | 67 | 7 anni | |
| Vimal Srivastava | M | 58 | 2 anni | |
| Christopher Schelling | M | 48 | 6 anni | |
| Min MIn Qin | M | 66 | 7 anni | |
| Alejandro Dorenbaum | M | 64 | 7 anni | |
| Suyash Prasad | M | 54 | 4 anni | |
| John Urquhart | M | - | - | |
| Eric B. Sjogren | M | 67 |
Syntex Corp.
| - |
| Erich Sager | M | 66 | 9 anni | |
| Todd C. Zankel | M | 60 | 8 anni | |
| David J. Loury | M | 68 |
Syntex Corp.
| 10 anni |
| Elizabeth Dávila | F | 80 |
Syntex Corp.
| 17 anni |
| Virgil Thompson | M | 84 |
Syntex Corp.
| 24 anni |
| Gordon Ringold | M | 73 |
Syntex Corp.
| 24 anni |
| Hugo Madden | M | 75 |
Syntex Corp.
| 18 anni |
| Emil Kakkis | M | 63 | 11 anni | |
| Stephen Aselage | M | 73 | 7 anni | |
| David J. Ellam | M | - | 6 anni | |
| Vijay Samant | M | 77 | 2 anni | |
| Leonard Post | M | 72 | 6 anni | |
| Matt Patterson | M | 52 | 6 anni | |
| Robert A. Heft | M | 69 | 3 anni | |
| Keith R. Bley | M | 64 |
Syntex Corp.
| 9 anni |
| S. Michael Imperiale | M | - | - | |
| Gordon Vehar | M | - | - | |
| Lewis Chapman | M | - | - | |
| Yasuhiro Hashimoto | M | 68 |
Syntex Corp.
| - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Jeffrey Cooper
- Contatti personali
